Elanix

Applying the healing properties of progenitor cell therapies to alleviate and heal a range of medical conditions – starting with dermatology and gynecology.

Elanix develops and markets progenitor cell-based products to help regenerate tissue and promote healing in the treatment of burns, and gynecological and dermatological conditions. The Company is headquartered in Nyon, Canton Vaud, Switzerland, with offices in Potsdam, Germany, and listed on the Frankfurt stock exchange under the symbol ELN.

SCIENTIFIC RATIONALE

Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix enhances the activity of progenitor cells with proprietary cytokine formulations to create unique cell therapy products and procedures.

PIPELINE

Our pipeline of progenitor cell products combines a development-stage, advanced biological bandage that promotes skin healing in deep burn victims and two enhanced OTC creams. GynRepair® is used by our customers to (sold in Switzerland since 2011) alleviate the symptoms of vulvodynia, a fairly common women’s health issue. RepAir-A® is a dermatological used to rejuvenate the skin following damage, e.g. from sun exposure or late-stage healing process after deep burns.

PARTNERS

BioReliance
CHUV
EasyWell
Sincopharm SA

INVESTOR RELATIONS

Financial information and stock performance data can be found in the Investor Relations sections in both English and German

NEWS